This site is intended for healthcare professionals outside the US.

DOUBLE YOUR IMPACT

 

AFINITOR plus exemestane more than doubled median PFS for patients after initial NSAI failure vs exemestane alone1

Early and sustained benefits with AFINITOR plus exemestane, based on local review1*†

“Early and sustained benefits with AFINITOR (everolimus) vs exemestane alone, based on local review. 90% of patients remained progression free at first assessment.”
  • Patients treated with AFINITOR plus exemestane experienced a 55% reduction in the risk of progression or death vs exemestane alone

Significant PFS benefit confirmed by independent review2*†

“Local Review: Median progression-free survival (PFS) of 11 months with AFINITOR (everolimus) plus exemestane vs exemestane alone”
  • Patients treated with AFINITOR plus exemestane experienced a 62% reduction in the risk of progression or death vs exemestane alone1

In the first-line metastatic setting after adjuvant NSAI failure, AFINITOR plus exemestane demonstrated greater PFS benefit vs exemestane alone3

“Local Review: In the first-line metastatic setting after adjuvant NSAI failure, AFINITOR (everolimus) plus exemestane demonstrated greater PFS benefit vs exemestane alone”
  • Patients treated with AFINITOR plus exemestane in the first-line metastatic setting after adjuvant NSAI experienced a 61% reduction in the risk of progression or death vs exemestane alone3

First-line PFS benefit in the first-line metastatic setting after NSAI failure confirmed by independent review3

“First-line progression-free survival (PFS) benefit in the first-line metastatic setting after NSAI failure, confirmed by independent review, of 15.2 months with AFINITOR (everolimus) plus exemestane vs 4.2 months with exemestane alone”
  • Patients treated with AFINITOR plus exemestane in the first-line metastatic setting after adjuvant NSAI experienced a 68% reduction in the risk of progression or death vs exemestane alone3

AFINITOR demonstrated a durable treatment benefit4

“AFINITOR (everolimus) plus exemestane more than doubled the number of patients progression free at 6, 12, and 18 months vs exemestane alone”
  • AFINITOR plus exemestane more than doubled the number of patients progression free at 6, 12, and 18 months4*
  • AFINITOR plus exemestane more than doubled median PFS, demonstrating a median PFS of 7.8 and 11.0 months vs 3.2 and 4.1 months, respectively2,3*
Abbreviations:
ABC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; CI, confidence interval; HR, hazard ratio; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival.
*Versus exemestane alone.
With kind permission from Springer Science+Business Media: Adv Ther. Everolimus Plus Exemestane in Postmenopausal Patients With HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. 2013;30(10):870-884. Yardley DA, Noguchi S, Pritchard KI, et al. Figure 1.
References:
  1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2016.
  2. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
  3. Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR+, HER2– advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014;143(3):459-467.
  4. Data on file. Novartis Pharma AG.